REPLIMUNE GROUP, INC. Operating Cash Flow
REPLIMUNE GROUP, INC. (REPL) reported Operating Cash Flow of -$75.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$75.73M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$56.16M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$65.95M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$81.21M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for fiscal 2026 was -$280.34M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$192.25M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$185.47M.
- REPLIMUNE GROUP, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$128.05M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$75.73M 10-Q · filed 2026-08-14 | -$131.89M derived: sum of 2 quarters · filed 2026-08-14 | -$197.84M derived: sum of 3 quarters · filed 2026-08-14 | -$279.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$56.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$122.12M derived: sum of 2 quarters · filed 2026-06-29 | -$203.33M derived: sum of 3 quarters · filed 2026-06-29 | -$280.34M 10-K · filed 2026-06-29 |
| 2025-12-31 | -$65.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03 | -$147.17M derived: sum of 2 quarters · filed 2026-02-03 | -$224.18M 10-Q · filed 2026-02-03 | -$277.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$81.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | -$158.23M 10-Q · filed 2025-11-06 | -$211.96M derived: sum of 3 quarters · filed 2026-08-14 | -$262.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$77.02M 10-Q · filed 2026-08-14 | -$130.75M derived: sum of 2 quarters · filed 2026-08-14 | -$181.46M derived: sum of 3 quarters · filed 2026-08-14 | -$220.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$53.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$104.44M derived: sum of 2 quarters · filed 2026-06-29 | -$143.08M derived: sum of 3 quarters · filed 2026-06-29 | -$192.25M 10-K · filed 2026-06-29 |
| 2024-12-31 | -$50.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03 | -$89.35M derived: sum of 2 quarters · filed 2026-02-03 | -$138.52M 10-Q · filed 2026-02-03 | -$184.69M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | -$38.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | -$87.81M 10-Q · filed 2025-11-06 | -$133.97M derived: sum of 3 quarters · filed 2025-11-06 | -$181.09M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$49.17M 10-Q · filed 2025-08-07 | -$95.33M derived: sum of 2 quarters · filed 2025-08-07 | -$142.46M derived: sum of 3 quarters · filed 2025-08-07 | -$186.05M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$46.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | -$93.29M derived: sum of 2 quarters · filed 2025-05-22 | -$136.88M derived: sum of 3 quarters · filed 2025-05-22 | -$185.47M 10-K · filed 2025-05-22 |
| 2023-12-31 | -$47.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12 | -$90.71M derived: sum of 2 quarters · filed 2025-02-12 | -$139.30M 10-Q · filed 2025-02-12 | -$172.10M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$43.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$92.18M 10-Q · filed 2024-11-12 | -$124.97M derived: sum of 3 quarters · filed 2024-11-12 | -$153.56M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$48.59M 10-Q · filed 2024-08-08 | -$81.38M derived: sum of 2 quarters · filed 2024-08-08 | -$109.97M derived: sum of 3 quarters · filed 2024-08-08 | -$143.18M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$32.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | -$61.38M derived: sum of 2 quarters · filed 2024-05-16 | -$94.59M derived: sum of 3 quarters · filed 2024-05-16 | -$128.05M 10-K · filed 2024-05-16 |
| 2022-12-31 | -$28.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | -$61.80M derived: sum of 2 quarters · filed 2024-02-08 | -$95.25M 10-Q · filed 2024-02-08 | -$117.81M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | -$33.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07 | -$66.67M 10-Q · filed 2023-11-07 | -$89.22M derived: sum of 3 quarters · filed 2023-11-07 | -$107.57M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$33.45M 10-Q · filed 2023-08-03 | -$56.01M derived: sum of 2 quarters · filed 2023-08-03 | -$74.36M derived: sum of 3 quarters · filed 2023-08-03 | -$97.32M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$22.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | -$40.91M derived: sum of 2 quarters · filed 2023-05-18 | -$63.87M derived: sum of 3 quarters · filed 2023-05-18 | -$82.18M 10-K · filed 2023-05-18 |
| 2021-12-31 | -$18.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | -$41.31M derived: sum of 2 quarters · filed 2023-02-09 | -$59.62M 10-Q · filed 2023-02-09 | -$75.75M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | -$22.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03 | -$41.27M 10-Q · filed 2022-11-03 | -$57.40M derived: sum of 3 quarters · filed 2022-11-03 | -$70.39M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$18.31M 10-Q · filed 2022-08-04 | -$34.44M derived: sum of 2 quarters · filed 2022-08-04 | -$47.43M derived: sum of 3 quarters · filed 2022-08-04 | -$64.61M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$16.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | -$29.12M derived: sum of 2 quarters · filed 2022-05-19 | -$46.30M derived: sum of 3 quarters · filed 2022-05-19 | -$61.39M 10-K · filed 2022-05-19 |
| 2020-12-31 | -$12.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-03 | -$30.17M derived: sum of 2 quarters · filed 2022-02-03 | -$45.26M 10-Q · filed 2022-02-03 | -$56.52M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-09-30 | -$17.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-04 | -$32.27M 10-Q · filed 2021-11-04 | -$43.53M derived: sum of 3 quarters · filed 2021-11-04 | -$59.27M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$15.09M 10-Q · filed 2021-08-06 | -$26.35M derived: sum of 2 quarters · filed 2021-08-06 | -$42.09M derived: sum of 3 quarters · filed 2021-08-06 | -$62.06M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | -$11.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | -$27.00M derived: sum of 2 quarters · filed 2021-05-20 | -$46.97M derived: sum of 3 quarters · filed 2021-05-20 | -$60.55M 10-K · filed 2021-05-20 |
| 2019-12-31 | -$15.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-04 | -$35.71M derived: sum of 2 quarters · filed 2021-02-04 | -$49.29M 10-Q · filed 2021-02-04 | -$55.32M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | -$19.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-05 | -$33.55M 10-Q · filed 2020-11-05 | -$39.59M derived: sum of 3 quarters · filed 2020-11-05 | -$45.69M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$13.58M 10-Q · filed 2020-08-07 | -$19.61M derived: sum of 2 quarters · filed 2020-08-07 | -$25.72M derived: sum of 3 quarters · filed 2020-08-07 | -$32.10M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$12.14M derived: sum of 2 quarters · filed 2020-06-03 | -$18.52M derived: sum of 3 quarters · filed 2020-06-03 | -$25.38M 10-K · filed 2020-06-03 |
| 2018-12-31 | -$6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13 | -$12.49M derived: sum of 2 quarters · filed 2020-02-13 | -$19.34M 10-Q · filed 2020-02-13 | -$23.58M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | -$6.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12 | -$13.24M 10-Q · filed 2019-11-12 | -$17.48M derived: sum of 3 quarters · filed 2020-06-03 | -$20.17M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | -$6.86M 10-Q · filed 2019-08-14 | -$11.09M derived: sum of 2 quarters · filed 2020-06-03 | -$13.79M derived: sum of 3 quarters · filed 2020-06-03 | -$17.38M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | -$4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$6.93M derived: sum of 2 quarters · filed 2020-06-03 | -$10.52M derived: sum of 3 quarters · filed 2020-06-03 | -$16.01M 10-K · filed 2020-06-03 |
| 2017-12-31 | -$2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | -$6.29M derived: sum of 2 quarters · filed 2019-02-14 | -$11.78M 10-Q · filed 2019-02-14 | |
| 2017-09-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | -$9.09M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$5.49M 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | -$7.08M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |